TD-4208 175 mcg
0136
Phase 1 small_molecule completed
Quick answer
TD-4208 175 mcg for Cardiac Repolarization in Healthy Subjects is a Phase 1 program (small_molecule) at Theravance Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Theravance Biopharma
- Indication
- Cardiac Repolarization in Healthy Subjects
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed